Games Workshop dropped a whole bunch of brand new previews for The Emperor's Children who are making a glorious return to the Grimdark future of Warhammer 40,000. New and returning characters make an ...

What are the best Warhammer games? Games Workshop has a complicated history with licensing its tabletop worlds. There were some great Warhammer Fantasy strategy games back in the ’90s, but the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Robute Guilliman and Lion El’Jonson are the only two loyalist Primarchs around and they need some back-up from their brothers. There are currently two loyalist Primarchs in 40k that can take to the ...

Religion plays a massive role in the Warhammer 40k setting, with the church known as the Ecclesiarchy holding massive social influence and temporal power within the Imperium of Man. Where there’s ...

The Corvus Cabal worships the Great Gatherer by taking treasures from the victims of their ambushes and assassinations. They believe the Archaon is an avatar of their god and as such, seek to gain his ...

If you want more great stories of action, courage, and tragedy, we have another guide to the best Warhammer 40k books. Our guides to the Warhammer 40k factions are packed with lore. If you’re only ...

Corvus Pharmaceuticals' stock plummeted ~40% after Phase 1 data for soquelitinib in atopic dermatitis showed mixed results, raising concerns about its efficacy. Phase 1 data for soquelitinib in AD ...

Mizuho views the selloff yesterday in shares of Corvus Pharmaceuticals (CRVS) following the Phase 1 data for soquelitinib in atopic dermatitis as “way overdone.” Mizuho found the data ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) just reported positive results from its phase 1 study using soquelitinib [CPI-818] for the treatment of patients with atopic dermatitis [AD]. Being that ...

Get 5 New Stock Recommendations Every Week Corvus Pharmaceuticals, Inc. CRVS released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.